CROSSJECT Share Price Euronext Paris
Equities
FR0011716265
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
10/07 | Markets Powered by Alternating Current | ![]() |
10/07 | Crossject Gets EUR7 Million Public Funding for New Epinephrine Product | MT |
Sales 2024 * | 8.1M 8.86M 740M | Sales 2025 * | 53M 57.96M 4.84B | Capitalization | 84.68M 92.61M 7.74B |
---|---|---|---|---|---|
Net income 2024 * | -10M -10.94M -914M | Net income 2025 * | 22M 24.06M 2.01B | EV / Sales 2024 * | 13.1 x |
Net Debt 2024 * | 21.7M 23.73M 1.98B | Net Debt 2025 * | 5.1M 5.58M 466M | EV / Sales 2025 * | 1.69 x |
P/E ratio 2024 * |
-8.24
x | P/E ratio 2025 * |
3.96
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.12% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 61 | 08/01/08 | |
Olivier Giré
PRN | Corporate Officer/Principal | - | 01/16/01 |
General Counsel | - | 01/13/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel Teper
BRD | Director/Board Member | 64 | 07/23/07 |
Eric Nemeth
BRD | Director/Board Member | 65 | - |
Philippe Monnot
CHM | Chairman | 65 | - |
1st Jan change | Capi. | |
---|---|---|
+15.72% | 250M |